Publication
Article
Pharmacy Times
Read about the new generic products featured in July.
Teva Pharmaceuticals
COMPARE TO: Lescol (Novartis)
INDICATION: Teva Pharmaceuticals recently announced the availability of Fluvastatin Sodium Extended-Release Tablets, the therapeutic equivalent to Novartis’ Lescol XL. The product is a lipid-lowering agent indicated as an adjunct to diet to treat primary hypercholesterolemia and mixed dyslipidemia.
DOSAGE FORMS: 80 mg
FOR MORE INFORMATION: tevapharm.com
METHYLPHENIDATE, USPMARKETED BY: Camber Pharmaceuticals, Inc
COMPARE TO: Ritalin (Novartis)
INDICATION: Camber Pharmaceuticals recently launched Methylphenidate, USP, the generic equivalent of Novartis’ Ritalin, in 5-, 10-, and 20-mg dosage strengths. The product is indicated to treat attention-deficit/hyperactivity disorder and narcolepsy.
DOSAGE FORM: Tablets: 5, 10, and 20 mg
FOR MORE INFORMATION: camberpharma.com
DOFETILIDE CAPSULESMARKETED BY: Mayne Pharma
COMPARE TO: Tikosyn (Pfizer)
INDICATION: Mayne Pharma recently announced the launch of its Dofetilide Capsules, the therapeutic equivalent to Pfizer’s Tikosyn. The product is an antiarrhythmic agent indicated to treat irregular heartbeats, such as in atrial fibrillation and atrial flutter.
DOSAGE FORM: Capsules: 125, 250, and 500 mcg
FOR MORE INFORMATION: maynepharma.com
DICLOFENAC SODIUM GEL 3%MARKETED BY: Taro Pharmaceuticals
COMPARE TO: Solaraze Gel (PharmaDerm)
INDICATION: Taro Pharmaceuticals recently announced the launch of its Diclofenac Sodium Gel 3%, the generic equivalent to PharmaDerm’s Solaraze. The topical gel is indicated to treat actinic keratosis. It should be applied twice daily to the lesion areas. Sun avoidance is indicated during therapy.
DOSAGE FORM: Gel: 3%
FOR MORE INFORMATION: taro.com